ClinicalTrials.gg
Not yet recruitingNCT06504602Updated Jul 18, 2024

Pain Elimination and Anxiety Control Through Experiential Virtual Reality

An interventional study of Active Virtual Reality and Passive Virtual Reality in Procedural Pain and Procedural Anxiety, sponsored by Children's Hospital Los Angeles. Not yet recruiting. Open to participants aged 8 Years to 21 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-18.

Sponsored by Children's Hospital Los Angeles · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 7 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
8 Years to 21 Years
Sex
All
01

Study summary

The goal of this clinical trial is to determine if active virtual reality is more effective than passive virtual reality and standard of care distraction in decreasing pain in children, from 8 to 21 years old, undergoing intravenous placement in emergency department. The main question[s] it aims to answer [is/are]:

  • Will active virtual reality reduce pain score on Faces Pain Scale - revised and measure of heart rate during intravenous placement for children ages 8 years old to 21 years old more than passive virtual reality and standard of care?
  • Will active virtual reality reduce anxiety score on Visual Analog Scale - revised and measure of heart rate during intravenous placement for children ages 8 years old to 21 years old more than passive virtual reality and standard of care?

If there is a comparison group: Researchers will compare active group to passive group and standard of care.

Participants will randomized into active virtual reality, passive virtual reality or standard of care arms.

02

Conditions studied

  • Procedural Pain
  • Procedural Anxiety

Browse trials for

03

In context

Pain, Procedural

241 studies on the registry are indexed under Pain, Procedural; 64 are open to participants now.

This study's planned enrollment of 96 is close to the median of 90 across 227 interventional studies indexed under Pain, Procedural.

Browse Pain, Procedural studies →

Lead sponsor

Children's Hospital Los Angeles is the lead sponsor of 152 studies on the registry; 46 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children and adolescents 8-21 years old undergoing IV placement .

    • Ability to understand study procedures and to comply with them for the entire length of the study.
    • Participants and caregiver speaking English or Spanish.

Exclusion criteria

Exclusion Criteria:

  • Participants with psychiatric, developmental delay, visual or auditory deficits that would interfere with virtual reality gameplay (decision based on treating clinicians' evaluation).

    • Participants receiving narcotics, opioids, or anxiolytics 8 hours prior (Tylenol and ibuprofen do not count).
    • Participants with pain so significant that consent/assent is not possible (decision based on treating clinician evaluation).
    • Critically ill Participants (ESI 1).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Active Virtual Reality

    Within the active virtual reality group virtual environment, participants will play the game Bearblast using Oculus Go Headset for patients 8-21 years old. In BearBlast, participants travel on a pre-set path through an interactive environment.

    Device: Active Virtual Reality

  • Experimental
    Passive Virtual Reality

    Within the passive virtual reality group virtual environment and age appropriate movie.

    Device: Passive Virtual Reality

  • No intervention
    Standard of Care

    Participants will receive standard of care distraction methods.

Interventions

  • DeviceActive Virtual Reality

    Active virtual reality group will play a game through a virtual environment.

  • DevicePassive Virtual Reality

    Passive virtual reality group will watch a movie through a virtual environment.

06

What researchers measure

Primary outcomes

  1. Mean Change from Baseline in Pain Scores on Faces Pain Scale - Revised after IV Placement

    Pain score on Faces Pain Scale - Revised will be assessed 5 minutes before and immediately after procedure. The minimum score is 0, and the maximum score is 10. Higher scores correlate to a worse outcome (more pain).

    Time frame: 5 minutes before, immediately after procedure

Secondary outcomes

  1. Mean Change from Baseline in Anxiety Scores on Visual Analog Scale after IV Placement

    Anxiety score on Visual Analog Scale will be assessed 5 minutes before and immediately after procedure. The minimum score is 0, and the maximum score is 100. Higher scores correlate to a worse outcome (more anxiety).

    Time frame: 5 minutes before, immediately after procedure

  2. Mean Change from Baseline in Heart Rate after IV Placement

    Heart Rate will be measured 5 minutes before, during, and immediately after procedure

    Time frame: 5 minutes before, during, and immediately after procedure

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2024; primary completion for Mar 2025, 6 months later.

Of 141 non-industry interventional studies with no phase under Pain, Procedural, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 15. This study's planned 6 months is below that.

Counting every sponsor, half of 141 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2024
First posted
Jul 17, 2024
StartEst.
Sep 1, 2024
Primary completionEst.
Mar 15, 2025
CompletionEst.
Mar 15, 2025
Last update
Jul 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06504602
Responsible party
Matan Paret (Principal Investigator, Children's Hospital Los Angeles) — Principal investigator
First posted
Jul 17, 2024
Start date
Sep 1, 2024 (estimated)
Primary completion
Mar 15, 2025 (estimated)
Completion
Mar 15, 2025 (estimated)
Last update
Jul 18, 2024

Study contacts

Matan Paret, MD
Contact
mparet@chla.usc.edu
3233764793
Matan Paret, MD
principal investigator · Children's Hospital Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion